Kitzerow’s Autism and the Comorbidities Theory
“Autism and the comorbidities co-occur because they are caused by the same thing: gene mutations that trigger a system wide stress response, activating a BH4 Shunt. The body prioritizes this attempt to biochemically resolve the stress response over maintaining typical development and typical function in biochemically predictable ways. However, because the stress response is triggered by a gene mutation, it does not turn off, resulting in a lifelong allostatic existence.”
What Is Kitzerow’s Autism and the Comorbidities Theory, Simplified?
Kitzerow’s Autism and the Comorbidities Theory proposes that genetic and epigenetic factors can keep the body’s allostatic stress-response systems turned on. In this state, the body shifts how it uses its resources, prioritizing survival over typical development and typical function. These shifts occur in biochemically predictable ways that link autism to its comorbidities and create clusters of phenotypes based on which stress-response system is active.
-
Yes. In Kitzerow’s model, BH4 is the central biochemical mechanism that helps the body shift resources during stress. When stress-response systems activate, BH4 redirects resources across different biological pathways through a redox-regulated shunt. These shifts can influence development and physiology, helping explain the biological link between autism and the comorbid conditions often seen alongside it.
-
BH4 (tetrahydrobiopterin) is a biochemical cofactor, meaning it helps the enzymes that are dependent on it perform their functions. These enzymes control important biological processes in the body.
-
BH4 helps several important enzyme pathways in the body work properly, including pathways involved in:
Nitric oxide signaling (NOS) – controls blood flow, immune responses, and cellular stress signaling
Dopamine production (Tyrosine hydroxylase / TH) – influences motivation, movement, and attention
Serotonin production (Tryptophan hydroxylase / TPH) – influences mood, sleep, and regulation
Phenylalanine metabolism (Phenylalanine hydroxylase / PAH) – converts phenylalanine into tyrosine, which supports brain chemistry
Ether lipid metabolism and cellular repair (AGMO) – helps regulate certain lipids involved in cellular maintenance and signaling
BH4 is not known to be used in any biological pathways outside of these systems. Because these pathways influence multiple systems in the body, changes in how BH4 dependent resources are allocated during stress (via the redox-regulated BH4 Shunt) can affect both brain function and other physiological systems at the same time. The outcomes are also predictable because this biochemical system is highly conserved.
-
A shunt is when the body redirects biochemical resources from one pathway to another. This allows the body to prioritize certain functions when responding to stress.
-
Epigenetic redox-sensitive protein shunts describe how changes in the cell’s chemical environment can shift how biological pathways are used.
In Kitzerow’s model, this process centers on BH4 and nitric oxide synthase (NOS). BH4 helps regulate how NOS functions. Depending on conditions inside the cell, NOS can:
produce nitric oxide (NO)
produce reactive oxygen species (ROS)
produce both, which can combine to form peroxynitrite
These molecules change the redox state of the cell, which is the balance between oxidative and protective chemical reactions.
When the redox state changes, certain proteins and pathways become more active while others become less active. This effectively shifts how resources are used across different biological systems, which is what the framework refers to as a protein shunt.
Over time, these shifts can influence gene regulation, development, and physiological function.
-
Allostasis is the process the body uses to maintain stability during stress. Instead of keeping everything the same, the body adjusts how its systems operate so it can respond to changing conditions.
During allostasis, biological systems shift activity to help the body manage stress and protect survival.
-
Homeostasis keeps the body stable by correcting deviations from a normal range. When something moves outside that range, feedback systems act to bring it back to its original set point.
Allostasis maintains stability in a different way. Instead of returning everything to the same set point, the body changes how its systems operate to meet the demands of stress or the environment.
In other words:
Homeostasis: restore the original balance.
Allostasis: adjust the system to handle new conditions.
If these adjustments remain active for too long, the body can enter allostatic overload, where the cost of maintaining that altered state begins to strain biological systems.
-
Stress-response systems activate when the body detects a threat to stability. These systems are the regulatory domains Kitzerow refers to as BioToggles.
Different types of stress can activate different BioToggles, including:
Immune system BioToggle – infections, inflammation, or pathogen exposure
Cellular repair BioToggle – physical injury, tissue damage, or cellular stress
Metabolism BioToggle – energy shortages, nutrient imbalance, or metabolic stress
Nervous system BioToggle – neurological stress such as excitotoxicity, seizures, or neural injury
Genetic regulation BioToggle – disruptions in genomic stability or epigenetic regulation
When a BioToggle activates, the body can shift its biochemical priorities toward survival functions, temporarily changing how resources are used across biological systems.
Kitzerow identified these BioToggles by categorizing patterns of redox-regulated protein inductions that occur during cellular stress. When these protein responses were grouped by the systems they support, five regulatory domains became clear.
-
When stress-response systems remain active for long periods, they can disrupt the body’s temporal systems, which Kitzerow refers to as BioDials.
BioDials regulate when biological processes occur and how they respond to environmental timing signals such as light cycles, seasonal changes, development, and aging. These temporally regulated systems coordinate the timing of protein activity so biological functions occur at the appropriate stage or under the appropriate conditions.
These temporal systems include:
Ultradian - which regulates short-cycle timing of protein synthesis and physiological processes occurring multiple times within a day.
Circadian rhythms – daily cycles that regulate sleep, hormones, metabolism, and brain activity
Circannual cycles – seasonal biological adjustments that coordinate metabolism, immunity, and repair with environmental changes
Development – the time-regulated progression of growth and maturation from childhood through adulthood
Aging and repair – the ongoing timing of cell turnover and tissue maintenance
When stress-response systems remain active, they can interfere with these temporal regulatory systems, altering how biological processes unfold over time and influencing development and physiological function.
Kitzerow delineated these BioDials by categorizing patterns of temporally regulated protein induction, identifying biological systems that control when processes occur and how they respond to environmental timing signals such as light cycles, seasonal changes, development, and aging.
-
Stress-response systems (BioToggles) can remain active for different lengths of time depending on the cause of the activation:
Situationally flipped – temporarily activated in response to a stressor and able to return to baseline once the stress resolves
Chronically stuck – remains active due to prolonged stress exposure or disrupted feedback regulation
Genetically locked – permanently altered due to mutations affecting regulatory proteins
In Kitzerow’s Autism and the Comorbidities Theory, the stress-response systems are typically chronic or genetically locked, which is why the traits and symptoms associated with autism are lifelong in this model.
In the broader Neurodivergent Biochemistry framework, BioToggles can also be situational or reversible, meaning different durations of activation can lead to different forms of neurodivergence and physiological outcomes.
-
In Kitzerow’s Autism and the Comorbidities Theory, autism traits are linked to a BH4-dependent AAAH shunt.
AAAH refers to the aromatic amino acid hydroxylase enzymes, which use BH4 to produce neurotransmitters such as dopamine and serotonin.
In this model, when stress-response systems remain active, BH4 is diverted away from AAAH enzymes. As a result:
Dopamine and serotonin synthesis are reduced
Transamination pathways are upregulated
Glutamate synthesis increases
This shift disrupts the excitatory–inhibitory balance in the brain.
The imbalance affects the cortico-striatal-thalamic loop, a brain circuit that regulates:
movement
habit formation
reward processing
Dysregulation in this circuit contributes to the behavioral and neurological traits associated with autism, as survival signaling takes priority over typical neurotransmitter regulation and neurodevelopment.
-
In Kitzerow’s Autism and the Comorbidities Theory, comorbid traits arise through redox-sensitive protein shunts regulated by NOS and the effects of allostatic overload.
As described earlier, BH4 regulates how nitric oxide synthase (NOS) functions. Depending on cellular conditions, NOS produces:
Nitric oxide (NO)
Reactive oxygen species (ROS)
Both NO and ROS, which react to form peroxynitrite
These molecules change the redox state of the cell, which regulates redox-sensitive protein pathways. This process activates some biochemical pathways while suppressing others, redirecting biological resources across the body’s regulatory systems.
These shifts alter how biological systems function. Over time, those altered functions lead to physiological changes that manifest as comorbid traits.
When stress-response systems remain active for long periods, this process also leads to allostatic overload, placing sustained strain on multiple biological systems and further contributing to the development of comorbid conditions.
-
In Kitzerow’s Autism and the Comorbidities Theory, comorbid traits cluster based on which regulatory systems are genetically or epigenetically activated, how long those systems remain active, and when disruption occurs in the body’s temporal systems.
Clusters form through the interaction of three key variables:
regulatory system domain – which BioToggle is activated
duration of activation – whether the stress-response system remains chronically active or genetically locked
BioDial disruption timing – when temporal systems such as circadian cycles, development, or aging are disrupted
Because these variables interact with one another, individuals develop similar clusters of traits within these categories, while still showing significant variation across phenotypes.
-
Phenotypic variation depends on several factors:
Which BioToggle is activated
How long the system remains active
The developmental stage when activation occurs
Which BioDial timing processes are involved
The biochemical pathways affected
The downstream physiological effects
Different combinations of these variables can lead to different traits or health outcomes.
FAQ: Kitzerow’s Autism and the Comorbidities Theory and the BH4 Pathway
This FAQ addresses common questions about Kimberly Kitzerow’s Autism and the Comorbidities Theoretical Model, also known as Kitzerow’s BH4 Pathway Hypothesis. The theory proposes that genetically and epigenetically induced dysregulation of BH4-dependent biochemical pathways may contribute to both autism traits and the medical comorbidities frequently observed alongside autism. The questions below clarify common misunderstandings about the model, explain how it was developed, and outline how the proposed biochemical mechanisms relate to neurodevelopment and systemic health.
-
Prior to Kitzerow’s Autism and the Comorbidities Theoretical Model, the scientific literature contained numerous studies reporting associations between autism and various biochemical markers. Researchers had documented differences in neurotransmitter metabolites, oxidative stress indicators, immune signaling molecules, nitric oxide activity, and metabolic pathway changes. The biochemical roles of BH4-dependent enzymes were also well established in areas such as dopamine and serotonin synthesis, nitric oxide production, and lipid metabolism. These findings were interpreted as correlative associations, meaning they were observed alongside autism but were not explained through a unified causal mechanism.
-
Before Kitzerow’s Autism and the Comorbidities Theoretical Model was developed, the available scientific data included biomarker studies showing altered dopamine, serotonin, and glutamate metabolism, oxidative stress markers, immune activation signals, and nitric oxide pathway activity in autism populations. In addition, biochemical databases documented the functions of human gene-coded proteins and the pathways they regulate. These datasets described individual molecular functions and reported correlations with autism but did not organize the findings into a causal framework explaining how the biochemical changes may be connected.
-
The novel contribution of Kitzerow’s Autism and the Comorbidities Theoretical Model is the construction of a causal biochemical cascade linking previously separate observations. By building a functional network of human gene-coded proteins and mapping autism-associated biomarkers onto that network, consistent points of dysregulation became visible. Kitzerow’s Autism and the Comorbidities Theoretical Model links each node within that cascade to specific autism traits, associated comorbid conditions, and the biological mechanisms explaining why those traits frequently cluster together. The model identifies BH4-dependent enzymatic pathways and redox-sensitive protein regulation as central mechanisms within this regulatory cascade.
-
No. Biomedical models of autism existed prior to Kitzerow’s Autism and the Comorbidities Theoretical Model. Earlier biomedical research proposed that biological factors such as immune activation, oxidative stress, mitochondrial dysfunction, neurotransmitter differences, metabolic abnormalities, or environmental exposures may contribute to autism. These models helped establish that autism has biological components and that physiological systems outside the brain may be involved. However, they typically examined individual biochemical pathways or one of the regulatory system domains in isolation, treating these findings as separate mechanisms.
What distinguishes Kitzerow’s Autism and the Comorbidities Theoretical Model is its structure. Rather than focusing on a single pathway, the model proposes a causal biochemical cascade linking genetic and epigenetic disruption of five regulatory system domains, the resulting effects across five temporal domain systems governing biological function, development, and repair, and the downstream physiological impacts across organ systems. Through BH4-dependent enzymatic pathways and redox-sensitive protein regulation, Kitzerow’s Autism and the Comorbidities Theoretical Model connects previously separate biomedical observations and links each node of the cascade to autism traits, associated comorbid conditions, and the biological mechanisms explaining why these traits frequently cluster together.
You can learn more about the differences between Kitzerow’s Autism and the Comorbidities Theoretical Model and existing biomedical autism pathology models here: https://www.kimberlyedu.org/response-to-existing-biochemical-autism-pathology-models
-
Autism research has produced decades of molecular findings, including altered neurotransmitter metabolites, oxidative stress markers, nitric oxide pathway changes, immune signaling differences, and metabolic pathway shifts. Prior to Kitzerow’s Autism and the Comorbidities Theoretical Model, these findings were treated as independent correlations rather than components of a unified framework with a central regulatory mechsnism
Kitzerow’s Autism and the Comorbidities Theoretical Model resolves this by organizing previously reported molecular observations into a causal biochemical cascade. In the model, each step of the cascade corresponds to specific genetically or epigenetically induced regulatory shifts in BH4-dependent enzymatic pathways or redox-sensitive protein signaling. Each node in the cascade is linked to a defined autism trait, a defined comorbid trait, and the biochemical mechanism explaining why these traits frequently cluster together.
-
Kitzerow’s Autism and the Comorbidities Theoretical Model is a systems biology framework because it integrates multiple layers of molecular regulation into a single causal model.
The framework connects
• genetic and epigenetic disruption of five regulatory system domains
• the resulting biochemical shifts across five temporal domain systems governing function, development, and repair
• and the downstream molecular cascade affecting neurotransmitter synthesis, redox signaling, and related biochemical pathways.
This structure explains autism traits, comorbid traits, and trait clustering within one integrated biochemical mechanism rather than through isolated pathways.
-
Kitzerow’s Autism and the Comorbidities Theoretical Model was developed through computational systems analysis of molecular biology data. Kimberly Kitzerow constructed a biochemical network of human gene-coded proteins organized by molecular function and regulatory role. Autism-associated biomarkers reported across the scientific literature were then mapped onto this network.
By comparing these biomarkers to the functional protein network, consistent points of regulatory disruption became visible. These disruptions aligned along BH4-dependent enzymatic pathways and redox-sensitive protein signaling, revealing a sequential biochemical cascade. Within Kitzerow’s Autism and the Comorbidities Theoretical Model, each node in this cascade corresponds to a specific regulatory shift linked to an autism trait, a comorbid trait, and the biochemical mechanism explaining why those traits cluster.
This methodology follows the steps of the scientific method, including observation, hypothesis formation, network-based testing, and data analysis.
Learn more about Kitzerow’s methodology here:
-
The molecular functions used in Kitzerow’s Autism and the Comorbidities Theoretical Model are already experimentally established within the biochemical literature. The enzymes, cofactors, and signaling pathways involved in neurotransmitter synthesis, nitric oxide regulation, and redox-sensitive protein signaling have been validated through decades of molecular biology research.
Autism biomarkers have also been collected across numerous studies and cross-referenced against the biochemical protein network constructed during development of Kitzerow’s Autism and the Comorbidities Theoretical Model. Because human genes are approximately 99.9% conserved across the population, these biomarkers provide population-level evidence that the molecular pathways identified in the model are disrupted in autistic individuals.
The contribution of Kitzerow’s Autism and the Comorbidities Theoretical Model is the causal organization of these validated molecular functions into a unified biochemical cascade explaining autism traits and associated comorbid traits. Experimental validation of the model therefore involves testing the predicted regulatory cascade rather than establishing the underlying biochemical functions themselves.
What remains is continued validation and testing of the model’s predicted cascade and regulatory mechanisms. That process has already begun through recent publications examining the relevant molecular pathways. Breakdowns of these studies and how they relate to Kitzerow’s Autism and the Comorbidities Theoretical Model can be found here:
-
Peer review is a journal publication process in which two to three reviewers evaluate a manuscript before a journal decides whether to publish it. It is a publication filter rather than the mechanism by which scientific ideas are experimentally validated.
When Kitzerow’s Autism and the Comorbidities Theoretical Model was first publicly presented in 2023, Kimberly Kitzerow was an independent researcher without institutional affiliation, a PhD, or laboratory backing. Because of this, she sought collaboration with established research institutions.
Between 2023 and 2024, Kitzerow visited the autism research center near her, the Waisman Center at the University of Wisconsin–Madison, several times requesting assistance and collaboration on the biochemical aspects of the model. She met with the center’s director and was told that the center did not have biochemistry experts available to evaluate or collaborate on the work.
In September 2023, anticipating that institutional collaboration might not occur, Kitzerow established a business to formally document and protect the intellectual framework surrounding the model. In January 2024, she also self-published the work on ResearchGate to create a publicly accessible record of the theory and its development timeline while continuing to pursue collaboration.
In 2024, Kitzerow raised funds to return to the University of Wisconsin–Madison to study bioinformatics in order to strengthen the computational and molecular biology analysis behind the model. After completing coursework with top grades, she again requested collaboration and was informed that collaboration on the model would likely require obtaining a PhD.
Kitzerow agreed and planned to begin applying to doctoral programs in the fall of 2025. However, before that process began, the model had already been widely and virally disseminated since 2023. In February 2025, the mechanisms and conclusions of Kitzerow’s Autism and the Comorbidities Theoretical Model were utilized without citation for the first time in a publication from Brazil. After that, additional studies began appearing every few months examining mechanisms or conclusions consistent with elements of the model.
Kitzerow reported these instances to the journals and universities affiliated with the studies. Responses were received but were dismissals. For example, Princeton sent a letter through a secured university system the day after Christmas that was set to expire within seven days whether it was opened or not. The University of California San Diego responded that not enough plagiarism had occurred to warrant a formal review.
Given these events, Kitzerow has chosen to continue developing and documenting Kitzerow’s Autism and the Comorbidities Theoretical Model independently while reassessing the circumstances under which she may pursue collaboration with academic institutions in the future.
Examples of publications utilizing mechanisms consistent with Kitzerow’s Autism and the Comorbidities Theoretical Model without citation can be reviewed here:
What is Kitzerow’s Autism and the Comorbidities Theory?
Genetic and epigenetic factors activate stress-response regulatory systems and trigger a BH4 Shunt, which simultaneously alters several BH4-dependent pathways. This includes dysregulated neurotransmitter synthesis through AAAH activity (reduced dopamine and serotonin output with increased glutamate via upregulated transamination pathways), changes in stress-adaptive signaling and endocannabinoid regulation through AGMO activity, and redox-driven biochemical pathway shifts through NOS uncoupling. These changes disrupt excitatory/inhibitory balance in the cortico-striatal-thalamic loop, producing autism traits. Over time, continued redox activation drives broader biochemical pathway shifts that contribute to systemic comorbidities. Regression may occur when excitotoxic stress exceeds neural tolerance. Distinct phenotypes emerge depending on which regulatory system or systems are genetically or epigenetically activated altering biochemical pathways in distinct ways as regulatory system effectors.
Brief Overview of Existing Literature That Supports Kitzerow’s Autism and the Comorbidities Theory - More detail can be found here.
Chronic allostasis, driven by epigenetic and genetic factors, initiates systemic changes in which and what forms of proteins are active, and the impact begins early and compounds over time, which may alter how the brain and body develop in childhood, function across the lifespan, and ultimately age (Hoffman et al., 2023; McEwen & Wingfield, 2003; Guidi et al., 2020; McEwen & Gianaros, 2014; Blair et al., 2014; Danese & MCEwen, 2012; Kallen et al., 2021). This cascade includes developmental alterations in neural and physical growth, immediate disruptions in systemic biochemical function, and symptomatic changes in neural circuitry (Arnsten, 2009; Mualem et al., 2024), which may become particularly impactful within the excitatory/inhibitory balance within the Cortico-Striatal-Thalamic Loop (CSTL), a network critical for motor planning, cognitive flexibility, emotional regulation, and executive function (Martel et al., 2022). These CSTL-specific disruptions contribute directly to many of the core behavioral characteristics associated with autism, and has been heavily linked to autism in the existing peer reviewed literature (Soghomonian, 2024; Abbot et al., 2018; Li & Pozzo-miller, 2020; Fuccillo, 2016; Di Martino et al., 2011).
BH4 acts as the redox-sensitive biochemical lynchpin within this model, influencing each toggle: supporting or diverging nitric oxide synthase (NOS) in the immune system toggle; redirecting aromatic amino acid hydroxylases (AAAHs) in the nervous system toggle toward or away from dopamine, serotonin, and melatonin synthesis—shunting their precursor aromatic amino acids into transamination pathways; supporting alkylglycerol monooxygenase (AGMO) in the cellular repair toggle, as it is the only enzyme capable of cleaving ether lipid bonds; and contributing to metabolic adaptation via NOS uncoupling, which leads to reactive oxygen species (ROS) production. (Fanet et al., 2021).
The Four Core Pillars of Kitzerow’s 2023 Autism and the Comorbidities Theory and the 2025 Research that Supports This Model
Pillar 1: Genetic and epigenetic mutations activate internal stress-response systems.
Evidence:
A 2025 Japanese study showed diverse autism-associated mutations converge on a common cellular stress response.
Research examining ASD-associated CNVs found shared activation of stress-adaptive signaling pathways across multiple genetic mutations.
Pillar 2: Stress-response activation redirects biochemical pathway activity through the BH4 Shunt.
Evidence:
A 2025 Bralian study published a systemic review referring to a theoretical model that redox regulated BH4 and its affected BH4 dependent pathways pathologically link autism and comorbid traits, biochemically linking autism and the comorbidities through the BH4 pathway.
Pillar 3: This disruption alters neurotransmitter synthesis and produces excitatory/inhibitory imbalance in the cortico-striatal-thalamic loop, contributing to autism traits.
Evidence:
Stanford research identified reticular thalamus hyperexcitability within CSTL circuitry linked to autism behaviors, and created a successful treatment targeting this mechanism.
Yale research examining glutamate receptors reports findings consistent with E/I imbalance and excitotoxic signaling.
Pillar 4: Redox-driven biochemical pathway shifts contribute to systemic comorbidities and phenotypic clustering.
Evidence:
Princeton research showed different categories of genetic mutations alter biochemical pathway activity that clusters autism and comorbid traits into different phenotypic and clinical outcomes.
Step 1: The Moment That Sparked Everything- nonverbal autistic daughter can't blow out a candle on her birthday cake leads to the realization that autism and the comorbidities, including nonverbality, are physiologically linked rather than being independent traits.
Step 2: Hypothesis - It is biologically implausible for autism traits and comorbid traits to co-occur systematically in each phenotype without a shared biochemical root mechanism. This is now called the Exclusivity Principle.
Step 3: Testing Methodology - Created a biochemical network of gene-coded proteins and mapped autism-associated biomarkers onto the network to identify convergent points of regulatory dysregulation.
Step 4: Conclusion - Kitzerow’s Autism and the Comorbidities Theory
- Core Mechanism: Autism arises from gene mutations and epigenetic factors that alter regulatory system behavior and constrain neural development and function. Comorbidities arise when stress-responsive BioToggle activation reallocates proteins via epigenetic redox-sensitive BH4 shunt trifurcation, producing predictable comorbidity clusters based on which regulatory system effectors are engaged. The timing and duration of BioToggle activation shape the comorbidity profile, with sustained activation increasing cumulative physiological impact via allostatic overload.
- Systems-Level Impact: BioToggles may be situationally triggered by environmental encounters, chronically activated when resolution fails, or genetically locked when mutations impair regulatory reset. Activation generates an allostatic response that is biochemically mediated through BH4-dependent regulation. Under cellular stress conditions GCH1 regulates BH4-dependent trifurcation of three epigenetic redox-sensitive shunts, producing predictable downstream effects across systems.
-
The BH4 Shunt and Autism Traits - (the AAAH's)
The Aromatic Amino Acid Hydroxylases are enzymes that are required for the creation the neurotransmitters dopamine, norepinephrine, epinephrine, serotonin, and melatonin.
BH4 is a required part of the recipe that combines with the AAAH’s to create these neurotransmitters.
Mechanism that Produces Autism Specific Traits: When BH4 is shunted, the precursor aromatic amino acids (phenylalanine, tryptophan, and tyrosine) are shunted towards transamination pathways. This alters glutamate activity. This change in glutamate activity/synthesis dysregulates the excitatory/inhibitory balance within the cortico striatal thalamic loop. The cortico striatal thalamic loop regulates movement, habit formation, and reward. This is what mechanistically alters neurodevelopment and behavior physiologically resulting in autism specific traits.
Validation: Stanford’s Neurodiversity Project reached out to me November 2023 asking for more information. Jan 2024 I petitioned for their help. August 2025 a team from Stanford published their version of a cure that targets this mechanism, E/I balance within a specific section of the cortico striatal thalamic loop called the reticular thalamic nucleus.
-
The BH4 Shunt and Comorbid Traits - (NOS Uncoupling)
Mechanism that Produces Comorbid Traits: The NOS shunt reflects redox-regulated, BH4-mediated control of nitric oxide synthase. The BH4 shunt modulates NOS coupling state, permitting regulated NOS uncoupling under stress conditions and shifting nitric oxide production toward reactive oxygen species generation. This redox shift selectively activates downstream epigenetic redox-sensitive protein shunts that function as regulatory system effectors.
Epigenetic Redox-Sensitive Protein Shunt Effectors Regulatory Architecture:
The BioToggles are five interdependent regulatory systems that respond to physiological stress through conserved, coordinated activation and context-dependent allostatic resource reallocation to support survival. Activation of the stress response disrupts the BioDials, prioritizing regulatory and survival demands over typical development and typical function in biochemically predictable ways.
The BioDials are four time-regulated protein synthesis mechanisms that maintain the body's steady kinetic flow of protein production across circadian, seasonal, developmental, and lifespan timescales. Preservation of this kinetic flow state is essential for continued physiological function and survival. Prolonged displacement of BioDial-regulated synthesis by stress-responsive BioToggle activity results in allostatic overload with biochemically predictable consequences, the comorbidities.
Individual Variation: Individual differences arise from two mechanisms: experience-driven neural development, which is primarily shaped postnatally by environmental input, and regulatory system activation, in which genetically and epigenetically constrained BioToggles are situationally activated beyond the genetic phenotype. The degree, duration, and timing of this BioToggle activation disrupt BioDial-regulated protein synthesis, reallocating resources toward survival and producing variation in development and function.
Timing Effects: Trait severity and presentation depend on when a gene mutation is functionally relevant, which regulatory system it affects, when BioToggles are activated relative to BioDial-regulated protein synthesis, and how experience shapes neural development and function.
BioToggle activation during sensitive developmental windows more strongly displaces developmental and maintenance processes, while experience-driven neural plasticity during these periods further refines or amplifies functional outcomes.
-
The BH4 Shunt and the Endocannabinoid System - (AGMO)
Mechanism: AGMO is a BH4 dependent enzyme. It is the only enzyme known to cleave the bond of ether lipids in humans. One such ether lipid is noladin ether, which creates 2-AG one of the most abundant endocannabinoids.
Other examples of ether lipids include plasmalogens, alkylglycerols, and platelet-activating factor (PAF).
The AGMO shunt impacts ether lipid cleavage required for endocannabinoid system activity, cellular repair activity, and detoxification. Disruption of noladin ether cleavage to 2-AG alters endocannabinoid signaling. Prolonged AGMO impairment contributes to lysosomal dysfunction, reduced repair capacity, and cumulative system wear.